Dactolisib Tosylate NEW
| Price | $42 | $59 |
| Package | 25mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-27 |
Product Details
| Product Name: Dactolisib Tosylate | CAS No.: 1028385-32-1 |
| Purity: 99.85% | Supply Ability: 10g |
| Release date: 2025/05/27 |
Product Introduction
Bioactivity
| Name | Dactolisib Tosylate |
| Description | Dactolisib Tosylate (BEZ235 Tosylate) is a dual kinase inhibitor targeting PI3K and mTOR, with IC50 values of 4, 75, 7, and 5 nM for PI3Kα, β, γ, and δ, respectively. It also inhibits mTORC1 and mTORC2. |
| In vitro | Dactolisib (BEZ235) exhibits IC50 values of 4 nM, 75 nM, 7 nM, and 5 nM against PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively. Furthermore, it demonstrates significant activity against mutant forms of PI3Kα, specifically PI3KαE545K and PI3KαH1047R, with IC50 values of 5.7 nM and 4.6 nM, respectively. Treatment with increasing concentrations of Dactolisib (BEZ235) leads to a dose-dependent reduction in cell proliferation in PTEN-null cell lines PC3M and U87MG, with an average GI50 ranging from 10 to 12 nM. Notably, in human tumor cell lines, it effectively and specifically blocks the aberrant activation of the PI3K pathway, leading to G1 arrest.[1] |
| In vivo | Dactolisib (BEZ235) (50 mg/kg) appears rapidly in plasma with a Cmax of 1.68 μM at 0.5 h and a C24h of 0.03 μM. BEZ235 is well tolerated, and displays disease stasis when administered orally. It enhances the efficacy of other anticancer agents.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 0.1 mg/mL (insoluble) DMSO : 30.6 mg/mL (47.7 mM), Sonication and heating are recommended. |
| Keywords | PI3K | p110δ | p110γ | p110β | p110α-H1047R | p110α-E545K | p110α | NVP-BEZ-235 Tosylate | NVP-BEZ235 Tosylate | mTORC2 | mTORC1 | mTOR | Dactolisib Tosylate | BEZ-235 Tosylate | BEZ 235 Tosylate | Autophagy |
| Inhibitors Related | L-Leucine | Myricetin | Erucic acid | Sapanisertib | (2S,3R,4S)-4-Hydroxyisoleucine | 3-Methyladenine | Isoprenaline hydrochloride | Quercetin | Inavolisib | Quercetin Dihydrate | Apilimod | Rapamycin |
| Related Compound Libraries | PI3K-AKT-mTOR Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Antioxidant Compound Library | Drug Repurposing Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $64.00/100mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-05-13 | |
| $100.00/1kg |
VIP3Y
|
Hebei Dangtong Import and export Co LTD
|
2023-03-17 | |
| $0.00/1kg |
VIP1Y
|
Wuhan Circle Star Chem-medical Technology Co.,Ltd
|
2025-01-17 | |
| $42.00/25mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-05-26 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY